Literature DB >> 3244722

Chronic administration of S-(-)-pentobarbital in pigeons and rats: tolerance development.

G R Wenger1.   

Abstract

The development of tolerance to pentobarbital and cross-tolerance to other barbiturates has been documented in both laboratory animals and man. This study was undertaken to determine the extent of tolerance development to S-(-)-pentobarbital in rats and pigeons receiving 10 mg/kg/day S-(-)-pentobarbital, PO. In addition, the extent of cross-tolerance was determined to R-(+)-pentobarbital and both isomers of secobarbital. Rats were trained to respond under a variable-interval 60-sec (V160) schedule of food presentation while pigeons were trained to respond under a multiple fixed-ratio 30, fixed-interval 600-sec schedule of food presentation. After responding had stabilized, dose-response curves were determined for R-(+)-pentobarbital, S-(-)-pentobarbital, R-(+)-secobarbital, and S-(-)-secobarbital in both species. Upon the completion of the acute dose-response curves, both rats and pigeons were given 10 mg/kg/day S-(-)-pentobarbital, PO for 30 consecutive days prior to the redetermination of all four dose-response curves. Upon the completion of this second determination of each curve, the daily administration of the S-(-)-pentobarbital was discontinued, and the rats and pigeons remained drug free for 30 days. Following this 30-day drug free period, dose-response curves for the isomers of both pentobarbital and secobarbital were redetermined for a third time.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3244722     DOI: 10.1016/0091-3057(88)90374-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  1 in total

1.  Cross-tolerance and enhanced sensitivity to the response rate-decreasing effects of opioids with varying degrees of efficacy at the mu receptor.

Authors:  M J Picker; J Yarbrough
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.